Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells 100 Shares of Stock

Key Points

• Regeneron director Arthur Ryan sold 100 shares on May 1 at an average price of $705.24 for $70,524 under a pre-arranged Rule 10b5‑1 plan, trimming his stake by about 0.57% to 17,503 shares (≈$12.34M).
• Strong quarterly results: Regeneron reported Q1 EPS of $9.47 (vs. $8.91 expected) and revenue of $3.61B, up 19% year‑over‑year, with analysts forecasting roughly 36.05 EPS for the year.
• Dividend and analyst outlook: The company declared a quarterly dividend of $0.94 (annualized $3.76, yield ~0.5%), and the consensus rating is a "Moderate Buy" with an average price target of $826.59.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Arthur Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company's stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $7.79 during mid-day trading on Monday, reaching $709.21. 554,077 shares of the company traded hands, compared to its average volume of 748,440. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The company has a market capitalization of $74.98 billion, a P/E ratio of 17.28, a P/E/G ratio of 1.60 and a beta of 0.30. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a fifty day moving average price of $756.81 and a 200-day moving average price of $737.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts' consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company's quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.22 EPS. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.05 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is presently 9.16%.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. increased its holdings in Regeneron Pharmaceuticals by 153.4% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company's stock valued at $67,969,000 after purchasing an additional 73,176 shares during the period. PGGM Investments raised its holdings in Regeneron Pharmaceuticals by 9.7% in the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company's stock worth $52,057,000 after purchasing an additional 8,187 shares in the last quarter. Sound Shore Management Inc CT bought a new position in Regeneron Pharmaceuticals in the third quarter worth $64,677,000. Rakuten Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at $33,121,000. Finally, Ellerson Group Inc. ADV increased its holdings in shares of Regeneron Pharmaceuticals by 49.2% during the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company's stock valued at $4,556,000 after acquiring an additional 2,671 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

REGN has been the subject of several recent analyst reports. TD Cowen boosted their price objective on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a "buy" rating in a report on Thursday, April 23rd. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a "buy" rating in a report on Friday. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating for the company in a report on Thursday. Piper Sandler initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They set an "overweight" rating and a $875.00 price objective for the company. Finally, Zacks Research lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $826.59.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.